Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...
With a budget of up to $20m, the collaboration will establish scalable, rapid manufacturing for recombinant-protein vaccines.
In a recent article published in JAMA Network Open, researchers estimate the vaccine effectiveness (VE) of NVX-CoV2373, a recombinant protein-based coronavirus disease 2019 (COVID-19) vaccine against ...
Amy Sheng (left) is Head of the CRO Program at Sino Biological US Inc. (PA, USA), and has expertise in cell, molecular biology, immunology and biochemistry. In this interview, Amy discusses the ...
CEPI will work with Samsung Biologics to establish a scalable, rapid manufacturing process for recombinant-protein vaccines.
CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine ...
Whole blood derived from six adult donors who were inoculated with BCG in their childhood was cultured with MDP1 alone, MDP1 in combination with G9.1, or in combination with the negative form of ...
FLORHAM PARK, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease ...
The new updated Comirnaty Pfizer COVID mRNA vaccine is seen here next to the Fluzone H,D. influenza vaccine at a Walgreens pharmacy in Torrance, Caifornia, on September 5, 2024. (Genaro Molina/Los ...
insights from industryAmy ShengHead of CROSino Biological In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO program at Sino Biological US Inc., about current developments in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results